Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Feb;31(1):183-91.
doi: 10.1007/s10637-012-9853-3. Epub 2012 Jul 11.

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy

Yong Sang Hong  1 , Jeeyun Lee, Kyu-pyo Kim, Jae-Lyun Lee, Young Suk Park, Joon Oh Park, Se Hoon Park, Sun Young Kim, Ji Yeon Baek, Jee Hyun Kim, Keun-Wook Lee, Tae-You Kim, Tae Won Kim
Affiliations
Clinical Trial

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy

Yong Sang Hong et al. Invest New Drugs. 2013 Feb.

Abstract

Background: To investigate the efficacy and safety of bevacizumab beyond first progression combined with doublet chemotherapy in patients with metastatic colorectal cancer.

Methods: This multicenter phase II study included 76 patients with metastatic colorectal cancer progressed after first-line bevacizumab plus doublet chemotherapy. Study treatment consisted of second-line continuation of bevacizumab plus crossover standard doublet chemotherapy, consisting of FOLFOX, CapeOX, or FOLFIRI. Bevacizumab was administered in doses of 5 mg/kg/2-week or 7.5 mg/kg/3-week according to the schedules of the combined regimen.

Results: Median progression-free survival (PFS) and overall survival (OS) was 6.5 months (95 % CI, 5.2-7.8) and 12.8 months (95 % CI, 8.8-16.9), respectively, with no significant differences according to combined doublet chemotherapy. The response rate (RR) was 17.1 % (95 % CI, 8.6-5.6) with no statistical significance between regimens (p = 0.053). The first-line RR and PFS did not affect the second-line efficacy outcomes; RR (14.0 % vs 21.2 %, p = 0.405), median PFS (5.6 vs 6.7 months, p = 0.335), and OS (15.4 vs 11.0 months, p = 0.383) were not different between previous responders and non-responders, and the median PFS (p = 0.186) and OS (p = 0.495) were not different either according to the length of first-line PFS; however, OS from the first-line chemotherapy was longer in patients with longer first-line PFS (26.4 vs 14.8 months, p = 0.010). Bevacizumab-related significant adverse events included proteinuria (1.3 %) and thromboembolism (1.3 %).

Conclusions: Bevacizumab beyond first progression could be considered a treatment strategy even in patients progressed after first-line bevacizumab plus doublet chemotherapy. Second-line efficacy outcomes did not differ according to the first-line responses.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Int J Clin Oncol. 2012 Dec;17(6):604-9 - PubMed
    1. Clin Cancer Res. 2002 Jan;8(1):221-32 - PubMed
    1. J Clin Oncol. 2008 May 10;26(14):2311-9 - PubMed
    1. J Clin Oncol. 2004 Jan 15;22(2):229-37 - PubMed
    1. J Clin Invest. 2000 Apr;105(8):R15-24 - PubMed

Publication types

MeSH terms

LinkOut - more resources